Advertisement
Research ArticleArticle

Hepatobiliary Transport Governs Overall Elimination of Peptidic Endothelin Antagonists in Rats

Yukio Kato, Sharif Akhteruzzaman, Akihiro Hisaka and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics February 1999, 288 (2) 568-574;

Abstract

The overall disposition and hepatobiliary transport of BQ-123, an anionic cyclopentapeptide, and three analogs were examined in rats in vivo. Total body clearance (CLtotal) and biliary excretion clearance (CLbile, p) exhibited 4- to 8-fold differences between the compounds, with those for BQ-485 and compound A having the highest and lowest values, respectively. The CLbile, p values of BQ-485, BQ-123, and BQ-518 were almost equal to theCLtotal, suggesting that hepatobiliary transport is the major elimination pathway for these compounds. Hepatic uptake clearance (CLuptake, vivo) and biliary excretion clearance (CLbile, h/fT), which was defined for the hepatic unbound concentration, were separately determined to examine the hepatic uptake and excretion processes, respectively. Both theCLuptake, vivo andCLbile, h/fT of BQ-485 were higher than those of BQ-123, whereas the corresponding values for BQ-518 were similar to those for BQ-123. TheCLuptake, vivo andCLbile, h/fT of compound A were, respectively, approximately two thirds and one half those of BQ-123, suggesting that the lower CLbile, pvalue is due to the low efficiency of both the uptake and excretion processes. The CLuptake, vivo of these four peptides in vivo was similar to the extrapolated values based on the carrier-mediated transport activity previously assessed in vitro in isolated rat hepatocytes. The primary active transport previously assessed in an in vitro study in canalicular membrane vesicles was also highest for BQ-485 and lowest for compound A, similar toCLbile, h/fT in vivo. Thus, the transporters on both the sinusoidal and canalicular membranes determine the efficiency of the peptide overall elimination from the circulation.

A variety of small peptides have been recently developed as therapeutic agents; these include endothelin antagonists (Nirei et al., 1993;Nishikibe et al., 1993), renin inhibitors (Ondetti et al., 1981), somatostatin analogs (Labmerts et al., 1985), and thrombin inhibitors (Eckhardt et al., 1996). The metabolic stability of these peptides to the action of peptidases has been improved by the introduction of unusual amino acids and other modifications. However, such peptidemimetic compounds do not generally remain long in circulating plasma in vivo due to their rapid biliary excretion. Pharmacokinetic studies in rats have shown that octreotide and angiopeptin, both somatostatin analogs (Cathapermal et al., 1991; Lemaire et al., 1989), and ditekiren, a renin inhibitor (Greenfield et al., 1989), are efficiently taken up by the liver and subsequently excreted as intact peptides in bile.

Biliary excretion is one of the principal elimination mechanisms for xenobiotics, including therapeutic agents. Carrier-mediated transport systems have been identified for uptake on the sinusoidal membrane and for biliary excretion on the canalicular membrane (Keppler et al., 1997; Lomri et al., 1996; Meier et al., 1997; Müller et al., 1997;Yamazaki et al., 1996). These transporters have also been reported to be involved in the biliary excretion of small peptides. For example, carrier-mediated transport systems on the sinusoidal membrane have been reported for peptides, including cholecystokinin (Gores et al., 1986,1989), renin inhibitors (Bertrams et al., 1991a,b), and somatostatin analogs (Ziegler et al., 1988, 1991). Transporters on the bile canalicular membrane for small peptides, including a renin inhibitor EMD-51921 (Ziegler et al., 1994), ditekiren (Takahashi et al., 1997), and octreotide (Yamada et al., 1996), are primary active transport systems that use ATP hydrolysis as their driving force.

BQ-123, an anionic cyclopentapeptide endothelin ETA receptor antagonist, also has pharmacokinetic characteristics similar to those of the other small peptides described above (Nakamura et al., 1996; Shin et al., 1996). Its elimination from plasma in rats after i.v. injection is rapid, with the early-phaseT1/2 being approximately 4 min (Nakamura et al., 1996). Within 1 h after injection, 86% of the dose is excreted in bile in its intact form (Nakamura et al., 1996). We previously reported that active transport systems on both sinusoidal (Nakamura et al., 1996; S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier and Y. Sugiyama, submitted for publication) and canalicular (Shin et al., 1997;Akhteruzzaman et al., 1999) membranes are involved in the biliary excretion of BQ-123 in rats. The uptake of BQ-123 by hepatocytes can be inhibited by anionic compounds such as the bile acid, taurocholate, and an organic anion, dibromosulfophthalein (Nakamura et al., 1996). The excretion of BQ-123 on bile canalicular membrane is mainly mediated by canalicular multispecific organic anion transporter (cMOAT) (Shin et al., 1997).

A series of BQ-123 derivatives were synthesized in the present study with the aim of producing a long-lasting endothelin antagonist. These derivatives include compound A, which also has a cationic moiety (Fukami et al., 1996); in light of the previous studies, this might be important for recognition by transporters on both sinusoidal and canalicular membranes. BQ-485, an anionic linear peptide (Itoh et al., 1993), and BQ-518, where the d-Val in BQ-123 has been substituted with d-thianylglycine (d-Thg) (Fukami et al., 1995), have also been synthesized. The purpose of the present study was to examine quantitatively the contribution of transport activity on sinusoidal and canalicular membranes to the net biliary excretion of these compounds. To this end, each transport activity was separately determined in vivo: integration plot analysis was performed for hepatic uptake clearance, and biliary excretion clearance, as defined in terms of the hepatic unbound concentration, was determined in a steady-state infusion.

Materials and Methods

Chemicals and Reagents.

BQ-123 (cyclo[d-Trp-d-Asp-l-Pro-d-Val-l-Leu]), BQ-485 (perhydroazepino-N-carbonyl-l-Leu-d-Trp-d-Trp), BQ-518 (cyclo[d-Trp-d-Asp-l-Pro-d-Thg-l-Leu]), and compound A (cyclo[d-Trp-d-Asp-l-Hyp(l-Arg)-d-Val-l-Leu]) were synthesized at the Tsukuba Research Institute of Banyu Pharmaceutical Co., Ltd. (Tsukuba, Japan). [Prolyl-3,4(n)-3H]BQ-123 (31.0 Ci/mmol) was purchased from Amersham (Buckinghamshire, UK). All other chemicals and reagents were commercial products of analytical grade.

Animals.

Male Sprague-Dawley rats, weighing approximately 250 to 300 g, were purchased from Nisseizai (Tokyo, Japan). This study was carried out in accordance with the “Guide for the Care and Use of Laboratory Animals” as adopted and promulgated by the National Institutes of Health.

Steady-State Infusion Study.

With the animals under light ether anesthesia, both the femoral artery and vein were cannulated with a polyethylene catheter (PE-50; Clay Adams, Parsippany, NJ) for blood sampling and drug infusion, respectively. The bile duct was also cannulated with a polyethylene catheter (PE-10; Clay Adams) for bile collection. After dissolving in saline, each peptide was infused over a period of 60 min. Bile was collected in preweighed test tubes at 10-min intervals. The plasma was prepared by the centrifugation of the blood samples (Microfuge E; Beckman, Fullerton, CA). At the end of the infusion, the liver was excised and weighed. The concentration of the drug in these samples was determined by high performance liquid chromatography (HPLC) method as described below. Based on the results obtained from the infusion study, pharmacokinetic parameters were calculated according to the following equations:CLtot=ICpss Equation 1CLbile,p=VbileCpss Equation 2CLbile,h=VbileChss Equation 3where I, Cpss,Vbile,Chss,CLtotal,CLbile, p, and CLbile, h represent infusion rate (nmol/min/kg), plasma concentrations at steady-state (μM), biliary excretion rate at steady-state (nmol/min/kg), hepatic concentration at steady-state (μM), total body clearance (ml/min/kg), biliary excretion clearance (ml/min/kg) defined with respect to plasma concentration, and biliary excretion clearance (ml/min/kg), defined with respect to hepatic concentration, respectively. Cpss was determined as the mean values of the plasma concentrations at 50 and 60 min.Vbile was determined as the biliary excretion rate from 50 to 60 min. Chsswas determined as the hepatic concentration at 60 min. To calculateChss, the specific gravity of the liver assumed to be unity. Thus, the amount in the liver (nmol/g liver) can be regarded as the hepatic concentration (μM), and the units ofCLbile, h should be ml/min/kg.

Integration Plot Analysis for Determination of In Vivo Hepatic Uptake Clearance (CLuptake, vivo).

After i.v. bolus injection (500 nmol/kg b.w.t.) via femoral vein, blood and bile samples were collected from the femoral artery and bile duct, respectively, for 3 min. During this period, a section of liver sample (100 mg) was resected at 30 s, 1.5 min, and 3 min by a biopsy technique. The concentration of the drug in the samples was determined by HPLC as described below. The plasma concentration-time profile was fitted to the following exponential equation by a nonlinear iterative least-squares method by use of a MULTI program (Yamaoka et al., 1981).Cp=A exp(−αt)+B exp(−βt) Equation 4where Cp is the plasma concentration, α and β are the apparent rate constants, A and B are the corresponding zero time intercept, and t is time. The area under the plasma concentration-time curve was calculated as:AUC=Aα1−exp(−αt)+Bβ1−exp(−βt) Equation 5Because the biliary excretion of the endothelin antagonists was rapid and at least a small portion of the peptide, once taken up by hepatocytes, was recovered in bile, the amount of peptide after uptake by the liver (Xliver) was calculated from the following equation:Xliver=Xliver,app+Xbile Equation 6where Xliver, app andXbile represent the amount of peptide in the liver and that recovered in bile, respectively. The integration plot was obtained by plottingXliver/Cpagainst area under the plasma concentration-time curve/Cp. The initial slope of the line represents the CLuptake, vivo.

HPLC Analysis of Endothelin Antagonists in Plasma, Bile, and Liver Samples.

Each plasma and bile sample was mixed with 4 volumes of ethanol and was centrifuged (2000g, 2 min). The concentration of peptides in supernatant was assayed by HPLC. Approximately 100 to 200 mg of liver sample was homogenized by a Polytron homogenizer (T25-S1; IKA Japan Co. Ltd., Yokohama, Japan) in 4 volumes of ethanol and then centrifuged. The concentration of the drug in the supernatant was determined by HPLC. The HPLC analysis was performed according to a published method (Nakamura et al., 1996) using a Spherisorb S3 ODS2 (4.6 × 150 mm) column (Tosoh, Japan). The mobile phase consisted of 0.1% (v/v) trifluoroacetic acid and 35% (v/v) acetonitrile for BQ-123, BQ-518, and compound A and 55% acetonitrile for BQ-485. A flow rate of 0.8 ml/min (BQ-485) and 1.0 ml/min (BQ-123, BQ-518, and compound A) and an injection volume of 50 μl were used for all experiments. The fluorescent detector was operated at an excitation wavelength of 287 nm and an emission wavelength of 348 nm. The detection limit was 30, 25, 30, and 20 pg for BQ-123, BQ-485, BQ-518, and compound A, respectively, with no background peaks. Recovery was 94%, 91%, 90%, and 74% for BQ-123, BQ-485, BQ-518, and compound A, respectively.

Determination of Plasma Protein Binding.

The plasma protein binding of the endothelin antagonists were determined by ultrafiltration. Each peptide dissolved in phosphate buffer (50 mM, pH 7.4) was diluted 10 times with rat plasma to give the final concentrations that were close to the steady-state plasma concentration present in the in vivo infusion study (0.370, 0.371, 0.595, and 1.54 μM for BQ-123, BQ-485, BQ-518, and compound A, respectively). The mixture was incubated at 37°C for 30 min to ensure binding equilibrium. After incubation, 40 μl of aliquot was taken for the determination of total plasma concentration. Next, the plasma was placed in an ultrafiltration apparatus (Centrifree; Amicon, Inc.,. Beverly, MA) with a molecular mass cutoff of 13 kDa and centrifuged at 3000 rpm (TOMY RL-100, Tokyo, Japan) for 10 min. After centrifugation, the concentration in filtrate was also determined by HPLC as the unbound concentration. The plasma unbound fraction (fu) was calculated by dividing the unbound concentration by the total plasma concentration. The recoveries of BQ-123, BQ-485, BQ-518, and compound A filtered through the system were 94.8%, 84.5%, 86.5%, and 96.2%, respectively. All the binding was normalized with respect to the filter blank.

Determination of Red Blood Cell Distribution.

Each peptide was dissolved in phosphate buffer (50 mM, pH 7.4) and diluted 10 times with rat whole blood to give the final concentration described above and incubated at 37°C for 30 min. To determine the concentration in whole blood, 50 μl of the blood was transferred into an Eppendorf tube immediately after incubation. The concentration was determined by the same HPLC method as used for plasma. After incubation, the blood was centrifuged at 3000 rpm (TOMY RL-100) for 10 min at 4°C to obtain the plasma. The concentration in plasma was determined by the HPLC method as described above. Blood-to-plasma concentration ratio (Rb) was calculated by dividing the concentration in whole blood by the plasma concentration.

Determination of Tissue Binding of Endothelin Antagonists in Liver.

Rat liver homogenate of 33.3% (w/v) was prepared using a Teflon homogenizer (Iuchi, Japan) in PBS (pH 7.4). This homogenate was serially diluted by PBS to make 16.6% and 8.3% homogenates. Each compound was then dissolved in 1 ml of these homogenate to give the concentration near to the steady-state hepatic concentration (2 μM for BQ-123, BQ-485, and compound A and 4 μM for BQ-518). Then, the mixture was incubated for 3 min at 37°C. After incubation, an aliquot was taken, and the concentration was determined by HPLC. This was designated as total concentration (Ct). Then, 600 μl of the mixture was placed in an ultrafiltration apparatus (Centrifree) and was centrifuged at 3000 rpm (TOMY RL-100) for 10 min. After centrifugation, the free concentration (Cf) in the filtrate was also determined by the HPLC method. The bound concentration in the tissue (Cb) was calculated by subtractingCf from Ct. After plotting Cb/Cfagainst the homogenate concentration, a straight line was obtained. TheCb/Cf at 100% homogenate concentration was then extrapolated, and nonspecific adsorption was subtracted from the extrapolated value. The unbound fraction in the liver (fT) was then calculated according to the following equation:fT=11+Y Equation 7where Y is the estimatedCb/Cfat 100% homogenate.

Extrapolation of Hepatic Uptake Clearance Based on In Vitro Data obtained in Isolated Rat Hepatocytes.

The permeability-surface area product across the isolated hepatocytes (PScell) was calculated according to the following equation using previously obtained data on the peptide in vitro uptake characteristics (S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier and Y. Sugiyama, submitted for publication):PScell=VmaxKm Na+­dependent+VmaxKm Na+­independent+Pdif Na+­dependent+Pdif Na+­independent Equation 8where Vmax, is the maximum uptake rate, Km is the Michaelis-Menten constant, and Pdif is the nonspecific uptake clearance. Using the calculatedPScell value from the in vitro data, the in vivo uptake clearance was predicted according to the following equation:CLuptake,vitro=Qp·fu·PScellQp+fu·PScell·1−HctRb Equation 9where CLuptake, vitro is the hepatic uptake clearance that is predicted from in vitro data,Qp is the hepatic plasma flow rate, and Hct is the hematocrit.Qp was 34.8 ml/min/kg, which was determined by the infusion study of taurocholic acid in our previous study (M. Kato, Y. Kato, T. Nakamura and Y. Sugiyama, submitted for publication). Hct was assumed to be 0.45.

Results

Plasma Concentration and Biliary Excretion Profiles of Endothelin Antagonists during Constant Infusion.

The plasma concentration of BQ-123, BQ-485, BQ-518, and compound A reached steady-state 50 min after the beginning of the i.v. infusion (Fig.1). TheCLtotal was the highest for BQ-485, followed by BQ-123, BQ-518, and compound A, which had a value about 4-fold smaller than that of BQ-485 (Table 1). The biliary excretion profile was also examined during the i.v. infusion (Fig. 2). The biliary excretion rate of BQ-123, BQ-485, and BQ-518 was close to the infusion rate (10 μg/min/kg) at steady-state (Fig. 2, Table 1), indicating very little metabolism of these three compounds. TheVbile of compound A was approximately 40% of the infusion rate (Fig. 2, Table 1). However, we found that compound A is hydrolyzed under the conditions presented by the physiological buffer, with the T1/2being about 180 min. Therefore, such degradation might also occur in vivo. The CLbile, p of BQ-485 was the highest, followed by that of BQ-123, BQ-518, and compound A, with an approximately 8-fold difference between BQ-485 and compound A (Table1). The CLbile, p of compound A was the lowest, being 13% that of BQ-123. The CLbile, h was also greatest for BQ-485, and there was an approximately 4-fold difference between BQ-485 and compound A (Table 1). ThisCLbile, h was defined in terms of the total (sum of unbound and bound) substrate concentration in the liver. TheCLbile, h/fT, which was defined in terms of the unbound substrate concentration in the liver, was calculated based on the data forCLbile, h and fT(Table 1). The CLbile, h/fT was much higher for BQ-485 than for the other peptides. The CLbile, h/fT for compound A was the lowest and approximately half that of BQ-123 (Table 1).

Figure 1
Figure 1

Plasma concentration-time profile of endothelin antagonists during i.v. infusion. Each point and vertical bar represent the mean ± S.E. of three animals. Infusion rate was 10 μg/min/kg b.wt.: ■, BQ-123; ⋄, BQ-485; ○, BQ-518; ▵,compound A.

View this table:
Table 1

Pharmacokinetic parameters for endothelin antagonists

Figure 2
Figure 2

Biliary excretion profile of endothelin antagonists during i.v. infusion. Each point and vertical bar represents the mean ± S.E. of three animals. Infusion rate was 10 μg/min/kg b.wt.: ■, BQ-123; ⋄, BQ-485; ○, BQ-518; ▵, compound A.

Integration Plot for Estimation of CLuptake, vivo.

The CLuptake, vivowas highest for BQ-485 and lowest for compound A (Fig.3, Table 1). TheCLuptake, vivo values for BQ-123 and BQ-518 were similar. The CLuptake, vivo for compound A was approximately half that of BQ-123 (Table 1).

Figure 3
Figure 3

Integration plot for the estimation of hepatic uptake clearance of endothelin antagonists. After i.v. bolus injection (500 nmol/kg) of each endothelin antagonists to the rat, plasma, bile, and liver samples were collected over 3 min. A–D, integration plots (seeMaterials and Methods for details) for BQ-123, BQ-485, BQ-518, and compound A, respectively. Data represents the mean ± S.E. of three animals.

Estimation of fu,Rb, and fT.

The fu, Rb, andfT were determined and shown in Table 1. ThefT was much lower for BQ-485 than that for other three compounds (Table 1).

Extrapolation of Hepatic Uptake Clearance from In Vitro Isolated Rat Hepatocyte Data.

Based on the extrapolation from the kinetic parameters previously obtained in vitro using isolated rat hepatocytes, the CLuptake, vitro was calculated and compared with the CLuptake, vivo observed in the present study (Fig. 4). TheCLuptake, vitro obtained in this way from in vitro data was close to the CLuptake, vivo(Fig. 4).

Figure 4
Figure 4

Comparison between hepatic uptake clearance observed in vivo and that predicted from in vitro data. The hepatic uptake clearance observed in vivo (CLuptake, vivo) was obtained from the initial slope of the integration plot shown in Fig. 3 and plotted against that predicted from the isolated rat hepatocyte data (CLuptake, vitro). The straight line indicates 1:1 correlation.

Discussion

It is established that peptidemimetic drugs, such as renin inhibitors, somatostatin analogs, and endothelin antagonists, are often efficiently excreted into the bile in an unchanged form, resulting in their low bioavailability (Bertrams et al., 1991a,b;Greenfield et al., 1989; Nakamura et al., 1996). However, the present study shows that both the CLtotal andCLbile, p differ between various endothelin antagonist. Compound A has a 4-fold lowerCLtotal than that of BQ-485 (Table 1).CLbile, p also differs between each compound, with an 8-fold difference between compound A and BQ-485 (Table 1). The inhibition constant of compound A for binding to ETA is in the nanomolar range, as in the case of BQ-485 and BQ-123 (22, 3.4, and 13 nM for BQ-123, BQ-485, and compound A, respectively) (Fukami et al., 1996; Itoh et al., 1993; Moreland et al., 1994). This means that it is possible to construct a small peptide, like compound A, that exhibits relatively lower hepatic extraction but still has potent antagonist activity. The order of the absolute value of CLbile, p(BQ-485 > BQ-123 > BQ-518 > compound A) was the same as that of CLtotal (Table 1). In addition, the biliary excretion ratio for BQ-485, BQ-123, and BQ-518 was almost equal to unity (Fig. 2). Therefore, the hepatobiliary transport of these endothelin antagonists determines the efficiency of their overall elimination from the body.

We previously reported that both the uptake and excretion processes of these four endothelin antagonists by sinusoidal and canalicular membranes, respectively, are mediated by active transport systems (S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier and Y. Sugiyama, submitted for publication;Akhteruzzaman et al., 1999). To understand the rate-determining process in the net biliary excretion of these endothelin antagonists, we attempted in this study to separately determine the clearance of the uptake process from the circulation into hepatocytes and the excretion process from the hepatocytes into bile. The difference inCLuptake, vivo, which represents the clearance for the uptake process, between each peptide (Table 1) suggests that the efficiency of hepatic uptake is highest for BQ-485 and lowest for compound A. The CLuptake, vivo was comparable with CLbile, p for both BQ-123 and BQ-485 (Table 1). This indicates that the rate-determining process for the net biliary excretion of these two compounds is uptake. Thus, once taken up by hepatocytes, the excretion of these compounds is much more rapid than by other trafficking processes (e.g., the net efflux from hepatocytes into the circulation). Accordingly, the difference in CLbile, p between BQ-123 and BQ-485 is due mainly to a difference in the efficiency of their uptake.

The CLuptake, vivo was smaller for compound A than for BQ-123, but this difference was not very marked and less than 2-fold (Table 1), suggesting that the large difference in net biliary excretion (CLbile, p) between these two compounds (Table 1) cannot be explained simply by a difference in efficiency of the uptake process at the sinusoidal membrane. To compare the efficiency of excretion across the bile canalicular membrane for each compound, we determinedCLbile, h in the infusion study (Table1). This CLbile, h is defined in terms of the total substrate concentration in the liver and therefore should be dependent on tissue binding in liver. If only unbound molecules can penetrate the bile canalicular membrane, the intrinsic transport activity on this membrane should be represented asCLbile, h/fT, which was defined in terms of the hepatic unbound concentration. TheCLbile, h/fT determined in the present study for compound A was lowest and only half that of BQ-123 (Table 1). Thus, the efficiency of the biliary secretion process also is one of the factors that determines differences in the degree of net biliary excretion.

To demonstrate that these in vivo kinetic parameters (CLuptake, vivo andCLbile, h/fT) directly reflect transport activity on sinusoidal and bile canalicular membranes, we compared these in vivo parameters with those extrapolated from data obtained in vitro in isolated rat hepatocytes and isolated rat bile canalicular membrane vesicles (CMV), respectively. In the hepatic uptake process, both Na+-dependent and -independent active transport mechanisms operate in the case of all four peptides (S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier and Y. Sugiyama, submitted for publication). Based on eqs. 8 and 9, hepatic uptake clearance can be predicted based on in vitro data, and theCLuptake, vitro thus obtained was almost the same as that observed in vivo (CLuptake, vivo) for each compound (Fig. 4). This demonstrates that the CLuptake, vivo observed in vivo in the present study reflects membrane transport across the sinusoidal membrane. On the other hand, cMOAT primarily mediates the transport of BQ-123, BQ-485, and BQ-518 in the excretion process on the bile canalicular membrane, whereas a primary active transporter other than cMOAT is responsible for the biliary excretion of compound A (Akhteruzzaman et al., 1999). The clearance for the ATP-dependent transport of BQ-123, BQ-485, BQ-518, and compound A in CMV was 11.3 ± 2.6, 29.3 ± 0.6, 7.53 ± 2.41, and 2.63 ± 1.03 μl/min/mg protein at a substrate concentration of 10 μM (Akhteruzzaman et al., 1999). Also, both theCLbile, h/fT (Table 1) and the clearance for the ATP-dependent transport observed in CMV (Akhteruzzaman et al., 1999) were highest for BQ-485 and lowest for compound A. Thus, the biliary excretion of peptides observed in vivo reflects membrane transport activity across the bile canalicular membrane.

The difference in CLuptake, vivo and CLbile, h/fT between BQ-123 and compound A was not very marked (less than 2-fold) compared with that inCLbile, p between each compound (an 8-fold difference). This may suggest that the difference in the efflux process from hepatocytes back into the circulation is also involved in determining such a large difference in CLbile, p between these compounds. In the present study, we actually determined the clearances for the net biliary excretion (CLbile, p), uptake process (CLuptake, vivo), and excretion process (CLbile, h/fT). Because the degree of metabolism of these compounds is minor, it is possible to calculate the efflux clearance for each compound based on these three parameters. Assuming the venous equilibrium model (Pang et al., 1977), the apparent intrinsic clearance (CLint, app) and the influx clearance across basolateral membrane (PS1) can be defined as:CLbile,p=Qp·fu·CLint,appQp+fu·CLint,app·1−HctRb Equation 10CLuptake,vivo=Qp·fu·PS1Qp+fu·PS1·1−HctRb Equation 11where CLint, app can be written as:CLint,app=PS1×CLbile,h/fTPS2+CLbile,h/fT Equation 12PS2 is the efflux clearance across the basolateral membrane. Based on the pharmacokinetic parameters obtained in the present study (Table 1), bothCLint, app andPS1 can be estimated for each peptide using eqs. 10 and 11, respectively. ThePS2 can then be calculated based on eq. 12. For both BQ-123 and BQ-485, the CLint, app was almost equal toPS1 because theCLbile, p was almost equal to theCLuptake, vivo for both compounds (Table 1). Therefore, based on eq. 12, thePS2 for these two compounds should be much less than their own CLbile, h/fT(PS2 ≪ 15.8 ml/min/kg for BQ-123 andPS2 ≪ 363 ml/min/kg for BQ-485). From our calculation, the PS2 for BQ-518 and compound A was 33.8 and 58.4 ml/min/kg, respectively. Thus, one of the reasons for the lower CLbile, p of compound A compared with BQ-123 may be its higher efflux across the basolateral membrane as well as its lower transport across the bile canalicular membrane. Further studies are needed to determine the PS2 for each peptide more directly and to identify the reason for this discrepancy inPS2 between the two compounds.

The present study (Fig. 4) shows that the hepatic uptake clearance, assessed by in vivo integration plot analysis, can be reasonably predicted for all four endothelin antagonists from the initial uptake rate obtained in vitro using freshly isolated hepatocytes. We have also confirmed this prediction for other therapeutic agents such as pravastatin (Yamazaki et al., 1993) and octreotide (Yamada et al., 1997), as well as the good agreement in influx clearance into hepatocytes between a liver perfusion system and isolated hepatocytes for 15 drugs with different membrane permeability (Miyauchi et al., 1993). These results indicate that in humans, too, the efficiency of the hepatic uptake of therapeutic agents can be predicted if their initial uptake rate can be determined in freshly isolated human hepatocytes. It might be difficult to predict the absolute values for hepatic uptake clearance in vivo in humans because freshly isolated human hepatocytes are not always available, and so the viability of human hepatocytes is critical. Nevertheless, the relative degree of uptake activity may be assessed for the different compounds. Therefore, such human hepatocyte systems are suitable for screening drugs during their developmental stage.

The present study has allowed us to conclude that hepatobiliary transport plays a major role in determining the overall elimination of endothelin antagonists from the circulation. The efficiency in net biliary excretion greatly differs between each compound and can be affected by transport activity in hepatic uptake across the basolateral membrane and/or biliary excretion across the bile canalicular membrane.

Footnotes

  • Send reprint requests to: Dr. Yukio Kato, Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: kato{at}seizai.f.u-tokyo.ac.jp

  • 1 This study was supported in part by a grant-in-aid for Scientific Research provided by the Ministry of Education, Science and Culture of Japan and in part by Core Research for Evolutional Science and Technology of Japan Science and Technology Corporation (J.S.T.).

  • Abbreviations:
    CMV
    canalicular membrane vesicle
    cMOAT
    canalicular multispecific organic anion transporter
    HPLC
    high-performance liquid chromatography
    fu
    the plasma unbound fraction
    Rb
    blood-to-plasma concentration ratio
    fT
    unbound fraction in the liver
    PScell
    permeability surface area product across the isolated hepatocytes
    PS1
    the influx clearance across basolateral membrane
    PS2
    the efflux clearance across the basolateral membrane
    • Received June 1, 1998.
    • Accepted September 9, 1998.

References

  1. ↵
    1. Akhteruzzaman S,
    2. Kato Y,
    3. Hisaka A,
    4. Sugiyama Y
    (1999) Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane. J Pharmacol Exp Ther 288:575–581.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Bertrams A,
    2. Ziegler K
    (1991a) New substrates of multispecific bile acid transporter in liver cells: Interference of some linear renin inhibiting peptides with transport protein(s) for bile acids. Biochim Biophys Acta 1073:213–220.
    OpenUrlPubMed
  3. ↵
    1. Bertrams A,
    2. Ziegler K
    (1991b) Hepatocellular uptake of peptides by bile acid transporters: Relationship of carrier mediated transport of linear peptides with renin inhibiting activity of multispecific bile acid carriers. Biochim Biophys Acta 1091:337–348.
    OpenUrlPubMed
  4. ↵
    1. Cathapermal SM,
    2. Foegh ML,
    3. Rau CS,
    4. Ramwell PW
    (1991) Disposition and tissue distribution of angiopeptin in the rat. Drug Metab Dispos 19:735–739.
    OpenUrlAbstract
  5. ↵
    1. Eckhardt U,
    2. Horz JA,
    3. Petzinger E,
    4. Stuber W,
    5. Reers M,
    6. Dickneite G,
    7. Daniel H,
    8. Wagner M,
    9. Hagenbuch B,
    10. Stieger B,
    11. Meier PJ
    (1996) The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide. Hepatology 24:380–384.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Fukami T,
    2. Nagase T,
    3. Fujita K,
    4. Hayama T,
    5. Niiyama K,
    6. Mase T,
    7. Nakajima S,
    8. Fukuroda T,
    9. Saeki T,
    10. Nishikibe M,
    11. Ihara M,
    12. Yano M
    (1995) Structure-activity relationship of cyclic pentapeptide endothelin A receptor antagonists. J Med Chem 38:4309–4324.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Fukami T,
    2. Niyama K,
    3. Amano Y,
    4. Hisaka A,
    5. Fujino N,
    6. Sawasaki Y,
    7. Ihara M,
    8. Ishikawa K
    (1996) Cyclic pentapeptide endothelin A receptor antagonists with attenuated in vivo clearance. Chem Pharm Bull 44:609–614.
  8. ↵
    1. Gores GJ,
    2. Kost LJ,
    3. Miller LJ,
    4. Larusso NF
    (1989) Processing of cholecystokinin by isolated liver cells. Am J Physiol 257:G242–G248.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Gores GJ,
    2. Larusso NF,
    3. Miller LJ
    (1986) Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol 250:G344–G349.
    OpenUrl
  10. ↵
    1. Greenfield JC,
    2. Cook KJ,
    3. O’Leary IA
    (1989) Disposition, metabolism and excretion of U-71038, a novel renin inhibitor peptide in the rat. Drug Metab Dispos 17:518–525.
    OpenUrlAbstract
  11. ↵
    1. Itoh S,
    2. Sasaki T,
    3. Ikeda K,
    4. Ishikawa K,
    5. Nishikibe M,
    6. Yano M
    (1993) A novel endothelin ETA receptor antagonist BQ-485 and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun 195:969–975.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Keppler D,
    2. Leier I,
    3. Jedlitschky G
    (1997) Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378:787–791.
    OpenUrl
  13. ↵
    1. Labmerts SWJ,
    2. Utterlinden P,
    3. Verschoor L,
    4. Van Dogen KJ,
    5. Del Pozo E
    (1985) Long-term treatment of acromegaly with somatostatin analogue SMS 201–995. N Engl J Med 313:1576–1580.
    OpenUrlPubMed
  14. ↵
    1. Lemaire M,
    2. Azria M,
    3. Dannecker R,
    4. Marbach P,
    5. Schweitzer A,
    6. Maurer G
    (1989) Disposition of sandostatin, a new synthetic somatostatin analogue in rats. Drug Metab Dispos 17:699–703.
    OpenUrlAbstract
  15. ↵
    1. Lomri N,
    2. Fitz JG,
    3. Scharschmidt BF
    (1996) Hepatocellular transport: Role of ATP-binding cassette proteins. Semin Liver Dis 16:201–210.
    OpenUrlPubMed
  16. ↵
    1. Meier PJ,
    2. Eckhardt U,
    3. Schroeder A,
    4. Hagenbuch B,
    5. Stieger B
    (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667–1677.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Miyauchi S,
    2. Sawada Y,
    3. Iga T,
    4. Hanano M,
    5. Sugiyama Y
    (1993) Comparison for the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat liver. Pharm Res 10:434–440.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Moreland S
    (1994) Endothelin receptor antagonists: A brief review. Can J Physiol Pharmacol 71:1469–1471.
    OpenUrl
  19. ↵
    1. Müller M,
    2. Jansen PL
    (1997) Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285–G1303.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Nakamura T,
    2. Hisaka A,
    3. Sawasaki Y,
    4. Suzuki Y,
    5. Ishikawa K,
    6. Yano M,
    7. Sugiyama Y
    (1996) Carrier mediated active transport of BQ-123, a peptidic endothelin antagonist into rat hepatocytes. J Pharmacol Exp Ther 278:564–572.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Nirei H,
    2. Hamada K,
    3. Shoubo K,
    4. Sogabe Y,
    5. Notsu Y,
    6. Ono T
    (1993) An endothelin ETA receptor antagonists FR139317 ameliorates cerebral vasospasm in dogs. Life Sci 52:1869–1874.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Nishikibe M,
    2. Tsuchida S,
    3. Okada M,
    4. Fukuroda T,
    5. Shimamoto K,
    6. Yano M,
    7. Ishikawa K,
    8. Ikemoto F
    (1993) Antihypertensive effect of a newly synthesized endothelin antagonist BQ-123 in a genetic hypertensive model. Life Sci 52:717–724.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Ondetti A,
    2. Cushman DW
    (1981) Inhibition of the renin-angiotensin system: A new approach to the therapy of hypertension. J Med Chem 24:355–361.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Pang KS,
    2. Rowland M
    (1977) Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow plasma and blood cell binding and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharm Biopharm 5:625–653.
  25. ↵
    1. Shin H,
    2. Kato Y,
    3. Shitara Y,
    4. Yamada T,
    5. Nakamura T,
    6. Hisaka A,
    7. Sugiyama Y
    (1996) The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123. J Pharmacol Exp Ther 278:607–613.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Shin H,
    2. Kato Y,
    3. Yamada T,
    4. Niinuma K,
    5. Hisaka A,
    6. Sugiyama Y
    (1997) Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. Am J Physiol 272:G979–G986.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Takahashi H,
    2. Kim RB,
    3. Perry PR,
    4. Wilkinson GR
    (1997) Characterization of the hepatic canalicular membrane transport of a model oligopeptide: Ditekiren. J Pharmacol Exp Ther 281:297–303.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Yamada T,
    2. Niinuma K,
    3. Lemaire M,
    4. Terasaki T,
    5. Sugiyama Y
    (1996) Mechanism of the tissue distribution and biliary excretion of the cyclic peptide octreotide. J Pharmacol Exp Ther 279:1357–1364.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Yamada T,
    2. Niinuma K,
    3. Lemaire M,
    4. Terasaki T,
    5. Sugiyama Y
    (1997) Carrier-mediated hepatic uptake of the cationic cyclopeptide octreotide in rats. Drug Metab Dispos 25:536–543.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Yamaoka K,
    2. Tanigawara Y,
    3. Nakagawa T,
    4. Uno T
    (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879–885.
    OpenUrlPubMed
  31. ↵
    1. Yamazaki M,
    2. Suzuki H,
    3. Hanano M,
    4. Tokui T,
    5. Komai T,
    6. Sugiyama Y
    (1993) Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36–G44.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Yamazaki M,
    2. Suzuki H,
    3. Sugiyama Y
    (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497–513.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Ziegler K,
    2. Frimmer M,
    3. Kessler H,
    4. Haupt A
    (1988) Azidobenzodiamido-008, a new photosensitive substrate for the ‘multispecific bile acid transporter’ of hepatocytes: Evidence for a common transport system for bile acids and cyclosomatostatins in basolateral membranes. Biochim Biophys Acta 945:263–272.
    OpenUrlPubMed
  34. ↵
    1. Ziegler K,
    2. Kolac C,
    3. Ising W
    (1994) ATP-dependent transport of the linear renin-inhibiting peptide EMD-51921 by canalicular plasma membrane vesicles of rat liver: Evidence of drug-stimulatable ATP-hydrolysis. Biochim Biophys Acta 1196:209–217.
    OpenUrlPubMed
  35. ↵
    1. Ziegler K,
    2. Lins W,
    3. Frimmer M
    (1991) Hepatocellular uptake of cyclosomatostatins: Evidence for a carrier system related to the multispecific bile acid transporter. Biochim Biophys Acta 1061:287–296.
    OpenUrlPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Hepatobiliary Transport Governs Overall Elimination of Peptidic Endothelin Antagonists in Rats

Yukio Kato, Sharif Akhteruzzaman, Akihiro Hisaka and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics February 1, 1999, 288 (2) 568-574;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement